Serhan Alkan, MD

Vice Chair, Director of Clinical Pathology
Director, Academic Clinical Pathology
Professor of Pathology
Director, Hematopathology
Director, Hematopathology Fellowship
Director, Personalized Medicine Diagnostics


Email: serhan.alkan@cshs.org
Phone: 310-423-5417


Specialties:

  • Hematopathology


Education and Training

  • Ege Medical University, Izmir, Turkey; MD
  • Residency in Anatomic and Clinical Pathology, George Washington University, Washington DC
  • Fellowship in Hematopathology, University of Michigan Medical Center, Ann Arbor, MI


Medical Board Certification

  • Board Certified, Anatomic Pathology
  • Board Certified, Clinical Pathology
  • Board Certified, Hematopathology


Clinical and Research Interests

  • Use of immunohistochemical and molecular markers in assessment of hematopoietic neoplasms
  • Analysis of intracellular signaling molecules that regulate survival of neoplastic cells


Awards and Activities

  • Described use of proteosome inhibitors as an effective therapy in treatment of multiple myeloma
  • Demonstrated potential use of Histone deacetylase inhibitors in treatment of leukemias and multiple myeloma


Selected Publications

  • Peker D, Alkan S, Zhang L, Martinez A. HIV-associated plasmablastic multicentric Castleman disease with microlymphoma coinfected with HHV8 and EBV. J Hematopathol. 2013;6:109-114.
  • Sojitra P, Gandhi P, Fitting P, Alkan S, Venkataraman G. Chronic Myelomonocytic Leukemia monocytes uniformly display a population of monocytes with CD11c under expression. Am J Clin Pathol. (In press).
  • Alkan S, et al. Bruton Tyrosine Kinase Is Commonly Overexpressed in Mantle Cell Lymphoma and Its Attenuation by Ibrutinib Induces. Leukemia Research. (In press).

Click here for a list of peer-reviewed publications by Serhan Alkan, MD.

Android app on Google Play